skip to content

Cambridge Immunology Network



The Cambridge Centre for Neuropsychiatric Research

The Bahn laboratory is conducting an extensive research program to define the molecular basis of major neuropsychiatric disorders. Our focus is on schizophrenia, bipolar affective disorder, major depressive disorder and autistic and anxiety spectrum disorders. The internationally recognized scientific team is supported by state of the art laboratory facilities at the Department of Chemical Engineering and Biotechnology, Cambridge. The Cambridge Centre for Neuropsychiatric Research (CCNR), under the direction of Prof Sabine Bahn conducts and coordinates fundamental and applied research into the causes and treatment of major neuropsychiatric disorders, focusing on biomarkers and novel target discovery with the mission to translate research findings from the bench to the patient bedside. Following its foundation in 2004 the Bahn lab has received the second largest centre grant awarded by the Stanley Medical Research Institute (SMRI) and has continually attracted support and interest from prominent pharmaceutical companies and clinical partners around the world.


Key publications: 

Schwarz E, van Beveren NJ, Ramsey J, Leweke FM, Rothermundt M, Bogerts B, Steiner J, Guest PC, Bahn S. (2012) Identification of Subgroups of Schizophrenia Patients with Changes in Either Immune or Growth Factor and Hormonal Pathways. Schizophr Bull. 2013 Aug 9.

Guest PC, Martins-de-Souza D, Schwarz E, Rahmoune H, Alsaif M, Tomasik J, Turck CW, Bahn S. (2013) Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med. 2013 Mar 26;5(3):25.

Ramsey JM, Schwarz E, Guest PC, van Beveren NJ, Leweke FM, Rothermundt M, Bogerts B, Steiner J, Ruta L, Baron-Cohen S, Bahn S. (2012) Molecular sex differences in human serum. PLoS One. 2012;7(12)

Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S. (2012) Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients Transl Psychiatry. 2012 Feb 21;2:e82. doi: 10.1038/tp.2012.3.

Bahn S, Noll R, Barnes A, Schwarz E, Guest PC. (2011) Challenges of introducing new biomarker products for neuropsychiatric disorders into the market. Int Rev Neurobiol. 2011;101:299-327. 

Emanuel Schwarz, Paul C. Guest, Hassan Rahmoune, Lan Wang, F. Markus Leweke, Matthias Rothermundt, Johann Steiner, Dagmar Koethe, Laura Kranaster, Patricia Ohrmann, Thomas Suslow, Michael Spain, Bernhard Bogerts, Nico (JM) van Beveren, George McAllister, Simon Baron-Cohen, Natalya Weber1, David Niebuhr1, David Cowan, Fuller Torrey E, Robert H Yolken, Sabine Bahn (2011) Identification of a Biological Signature for Schizophrenia in Serum. Mol Psychiatry. 2011 Apr 12.


Chan MK, Tsang TM, Harris LW, Guest PC, Holmes E, Bahn S. (2010) Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol Psychiatry. 2010 Oct 5.

Professor Sabine  Bahn
Not available for consultancy